Professional background

Dr Rowan Miller is a consultant medical oncologist specialising in gynae-oncology and early phase clinical trials at University College London and St Bartholomew's Hospitals.

Dr Miller completed her undergraduate training at the University of Oxford and clinical training at Guy's and St Thomas' Hospitals, London. She trained in medical oncology at University College London and was subsequently awarded a Cancer Research UK fellowship and attained a PhD from the Institute of Cancer Research. Following her PhD, Rowan completed a fellowship at Dana Farber Cancer Institute, Harvard University.

Rowan is involved in a number of clinical trials and basic science research projects across the two academic centres and is a member of the ESMO Personalized Medicine and Translational Research Committee.

Research interests

Clinical trials

  • Novel therapies for gynaecological cancer
  • Utilising genomics and biomarkers to guide therapy in patients
  • Clear cell ovarian cancer and other rare gynaecological cancers


Miller RE, Leary A, Scott C, Serra V et al. ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer. Annals of Oncology. 020 Sep 28;S0923-7534(20)42164-7.

Gourley C, Miller RE, Hollis RL & Ledermann JA. Role of PARP inhibitors beyond BRCA mutated ovarian tumours; definition of homologous recombination deficiency? Current Opinions in Oncology. 2020 Sep;32(5):442-450

Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim JS , Carreira S, Roda D, Miller R, et al Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Cancer Discovery. 2020 Jun 12; doi: 10.1158/2159-8290.CD-20-0163

Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R et al. Platinum sensitive relapsed high-grade serous ovarian cancer patients: real world UK clinical outcomes prior to PARP inhibitor introduction: International Journal of Gynecological Cancer. 2020 Jul;30(7):1026-1033.

Crusz SM and Miller RE. Targeted Therapies in Gynaecological Cancers. Histopathology. 2020 Jan;76(1):157-170
Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T, Miller R et al. ESMO recommendations on microsatellite instability testing in cancer, and its relationship with PD-1/PD-L1 expression and tumor mutational load: a systematic review-based approach. Annals of Oncology May 2019.

Miller RE, Crusz SM and Ledermann JA. Olaparib maintenance for first-line treatment of ovarian cancer- Will SOLO1 reset the standard of care? Future Oncology 2019. 2019 Jun;15(16):1845-1853

Miller RE and Ledermann JA. The European Society for Medical Oncology 2016 Congress: Highlights and summary of selected abstracts in gynecologic cancers. Gynecologic Oncology 2017 Jan;144(1):8-10.

Williamson CT, Miller R, Pemberton H, Jones SE, Campbell J, Kigozi A, Badham N, Rafiq R, Brough R, Gulati A, Ryan C, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A and Lord CJ. ATR inhibitors as a Synthetic Lethal Therapy for Tumors Deficient in ARID1A. Nature Communications 2016 Dec 13;7

Miller RE and Ledermann JA. The status of PARP inhibitors in ovarian cancer. Part 2: Extending the scope beyond olaparib and BRCA 1/2 mutations. Clinical Advances in Hematology and Oncology 2016 Sep;14(9):704-11.

Miller RE and Ledermann JA. The status of PARP inhibitors in ovarian cancer. Part 1: Olaparib. Clinical Advances in Hematology and Oncology. Clinical Advances in Hematology & Oncology. 2016 Aug;14 (8):619-627

Miller RE, Brough R, Bajrami I, Williamson C, McDade S, et al Synthetic Lethal Targeting of ARID1A Mutant Ovarian Clear Cell Tumours with Dasatinib. Mol Cancer Ther. 2016 Jul;15(7):1472-84

Kristeleit RS, Miller RE and Kohn EC. Gynecological Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. Am Soc Clin Oncol Educ Book. 2016;35:e259-68

Bajrami I, Frankum JR, Konde A, Miller RE, et al. Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP 1/2 Inhibitor Sensitivity. Cancer Research. 2014; 1;74(1):287-97

Miller RE and Banerjee S. The current state of pemetrexed in ovarian cancer. Expert Opinion Investigational Drugs. 2013; 22(9):1201-10

Neijenhuis S*, Bajrami I*, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair (Amst). 2013; 1;12(6):394-402 * Co-first authors

Tan DS*, Miller RE* and Kaye SB. New perspectives on molecular targeted therapy in ovarian clear carcinoma. Br J Cancer. 2013; 30;108(8):1553-9. * Co-first authors

Miller RE and Rustin GSJ. How to follow up patients with advanced epithelial ovarian cancer. Current Opinions in Oncology. 2010; 22(5):498-502